TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS

应激反应通路中蛋白质的异常功能(如P53、NF-B、热休克反应)是许多癌症类型的显著特征。这种改变与肿瘤对传统抗肿瘤治疗的不良反应有关。非小细胞肺癌、肝细胞癌、晚期前列腺癌、肾细胞癌和多形性胶质母细胞瘤等癌症也是如此。针对这些改变的靶向治疗可能会恢复肿瘤对治疗的反应，从而改善临床结果。多功能药物，如将在本合同范围内研究的Curaxin，有可能比靶向单一途径的药物更有效，因为它们降低了肿瘤找到方法绕过其影响的可能性，而不像单一功能药物那样，靶向途径的一个组成部分的突变或失活会使肿瘤对治疗不那么敏感。

Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor response of tumors to conventional antitumor treatments. This is true for such cancers as non-small cell lung cancer, hepatocellular carcinoma, advanced prostate cancer, renal cell carcinoma and glioblastoma multiforme. Targeted therapies against these alterations may restore tumor response to treatment and, thus, improve clinical outcome. Multifunctional agents, such as the Curaxin to be studied in the context of this contract, have the potential to be more effective than drugs that target single pathways since they decrease the likelihood of tumors finding ways to circumvent their effects unlike single function agents where one mutation or inactivation of a component of the targeted pathway would make tumors less sensitive to treatment.